Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.

Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, Hovingh GK, Kastelein JJ.

Circ Cardiovasc Genet. 2009 Apr;2(2):173-81. doi: 10.1161/CIRCGENETICS.108.818062. Epub 2009 Feb 12.

PMID:
20031582
[PubMed - indexed for MEDLINE]
Free Article
2.

An association study of 43 SNPs in 16 candidate genes with atorvastatin response.

Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ.

Pharmacogenomics J. 2005;5(6):352-8.

PMID:
16103896
[PubMed - indexed for MEDLINE]
3.

Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.

Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK.

DNA Cell Biol. 2010 Oct;29(10):629-37. doi: 10.1089/dna.2009.1008.

PMID:
20578904
[PubMed - indexed for MEDLINE]
4.

Genome-wide association of lipid-lowering response to statins in combined study populations.

Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, Li X, Wilke RA, Rieder MJ, Williams PT, Ridker PM, Chatterjee A, Rotter JI, Nickerson DA, Stephens M, Krauss RM.

PLoS One. 2010 Mar 22;5(3):e9763. doi: 10.1371/journal.pone.0009763.

PMID:
20339536
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators.

Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.

PMID:
17719314
[PubMed - indexed for MEDLINE]
6.

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators.

Lancet. 2006 Sep 9;368(9539):919-28.

PMID:
16962881
[PubMed - indexed for MEDLINE]
7.

Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.

Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE; Swiss HIV Cohort Study.

Circ Cardiovasc Genet. 2009 Dec;2(6):621-8. doi: 10.1161/CIRCGENETICS.109.874412. Epub 2009 Sep 18.

PMID:
20031643
[PubMed - indexed for MEDLINE]
Free Article
8.

Pharmacogenetic study of statin therapy and cholesterol reduction.

Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM.

JAMA. 2004 Jun 16;291(23):2821-7.

PMID:
15199031
[PubMed - indexed for MEDLINE]
9.

Impact of variants within seven candidate genes on statin treatment efficacy.

Vrablík M, Hubáček JA, Dlouhá D, Lánská V, Rynekrová J, Zlatohlávek L, Prusíková M, Ceška R, Adámková V.

Physiol Res. 2012;61(6):609-17. Epub 2012 Oct 25.

PMID:
23098650
[PubMed - indexed for MEDLINE]
Free Article
10.

Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators.

J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041.

PMID:
19497447
[PubMed - indexed for MEDLINE]
Free Article
11.

Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.

Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA.

Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.

PMID:
20130232
[PubMed - indexed for MEDLINE]
Free Article
12.

Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

Sharma R, Mahajan M, Singh B, Bal BS, Kant R.

J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498.

PMID:
17388006
[PubMed - indexed for MEDLINE]
13.

Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E.

J Am Coll Cardiol. 2008 Jan 29;51(4):449-55. doi: 10.1016/j.jacc.2007.10.017.

PMID:
18222355
[PubMed - indexed for MEDLINE]
Free Article
14.

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.

Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017.

PMID:
18640465
[PubMed - indexed for MEDLINE]
15.

Identification of genetic markers associated with high-density lipoprotein-cholesterol by genome-wide screening in a Japanese population: the Suita study.

Hiura Y, Shen CS, Kokubo Y, Okamura T, Morisaki T, Tomoike H, Yoshida T, Sakamoto H, Goto Y, Nonogi H, Iwai N.

Circ J. 2009 Jun;73(6):1119-26. Epub 2009 Apr 10.

PMID:
19359809
[PubMed - indexed for MEDLINE]
Free Article
16.

A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ.

Atherosclerosis. 2005 Jun;180(2):407-15.

PMID:
15910869
[PubMed - indexed for MEDLINE]
17.

Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.

Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V; TNT Steering Committee and Investigators.

Heart. 2008 Apr;94(4):434-9. Epub 2007 Dec 10.

PMID:
18070940
[PubMed - indexed for MEDLINE]
18.

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, Donnan PT, Palmer CN.

Pharmacogenet Genomics. 2008 Dec;18(12):1021-6. doi: 10.1097/FPC.0b013e3283106071.

PMID:
18815589
[PubMed - indexed for MEDLINE]
19.

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.

Curr Med Res Opin. 2002;18(4):220-8.

PMID:
12201623
[PubMed - indexed for MEDLINE]
20.

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.

Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):211-21.

PMID:
17056835
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk